Quantum BioVenture Studio | Collaboration Catalyst

This week marked a significant milestone in advancing the science park vision of BVI.EU’s Quantum Biospace TechBio science park project. Together with our partners, Invest.BW represented by Xavier Bocquet and Pierre de Waha, and TRAIL- Trusted AI Labs represented by Prof Benoît Macq, we launched the development of Quantum BioVenture, a pioneering TechBio venture builder studio focused on AI-driven drug discovery.

During this Collaboration Catalyst event, we brought together a distinguished assembly of disease biology researchers, leading providers of cutting-edge AI/ML and bioinformatics tools & services, accomplished drug hunters, top executives from biopharmaceutical R&D, innovative biotech entrepreneurs, and experts in health data access.

We express heartfelt gratitude to our esteemed guest speakers Prof Jean-Luc Balligand and Prof Olivier Devuyst from UCLouvain, Prof Bart Loeys from UAntwerp, Romain Alderweireldt from 101Genomes, Graham Ball and Robert Grundy from IntelligentOmics, Jan Szollos from Insilico Medicine and Pierre de Waha from Invest.BW for sharing their success stories in AI-powered target identification and drug discovery. We extend a warm thank you to all attendees for their active engagement and creativity during the interactive sessions focused on fostering partnership intentions.

We eagerly anticipate the next milestone before summer, which will involve onboarding early-stage partners to collaboratively shape the comprehensive portfolio strategy and operating model for Quantum BioVenture.

We are incredibly proud that Quantum BioVenture Studio was selected by the BW2030 consortium as a key initiative within the strategic development plan for Walloon Brabant and already received the BW2030.